HAEMONETICS CORP — Director's Dealing 2025

Jun 13, 2025

SEC Form 4/A — Form 4/A

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-05-16

Reporting Person: Galvin Roy (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-16	Common Stock	A	5689	—	Acquired	12932	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-16	Non-qualified Stock Option (Right to Buy)	$70.31	A	12317	Acquired	2032-05-16	Common Stock (12317)	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 6,755 instead of 5,689. This net decrease of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person.

F3: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F4: This number includes unvested RSUs previously reported.

F5: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 14,626 instead of 12,317. This net decrease of 2,309 options will be reflected in future filings by the reporting person.

F6: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.